The FDA released final guidance establishing a clear framework for how drug companies can develop, distribute, and label apps used alongside their prescription medicines.
This guidance clarifies when app content is subject to FDA submission requirements, when an app should be mentioned on a drug’s official label, and what materials companies should submit to the FDA.
The guidance identifies two categories of companion software:
- Apps connected to a medical device (such as an app paired with an asthma inhaler), which generally should be described on the drug’s official prescribing label, given the central role the software plays in how the medicine is used
- Standalone apps (such as symptom trackers, dose reminders, or health coaching tools), which should appear on the prescribing label if the company can show the app is essential for safe and effective use or can demonstrate a meaningful clinical benefit. In most cases, content a companion app displays to users will be treated as promotional material, consistent with how the FDA handles other drug advertising
By providing clear, practical recommendations for both drug-connected software and standalone software, the agency aims to reduce unnecessary uncertainty for developers and manufacturers while preserving the safety and effectiveness standards that patients and healthcare providers rely on.
For ongoing coverage of the latest drug information and alerts impacting workers’ comp, visit Med Monitor online.





